高级检索

益髓健脾汤联合XELOX化疗对结直肠癌患者免疫功能及肠道菌群的影响

Effects of Yisui Jianpi Decoction combined with XELOX chemotherapy on immune function and gut microbiota in patients with colorectal cancer

    摘要
  • 摘要:
    目的 探讨益髓健脾汤联合XELOX化疗方案对结直肠癌(CRC)患者免疫功能及肠道菌群的影响。
    方法 选取80例CRC患者作为研究对象，随机分为对照组(40例, XELOX化疗方案)、观察组(40例, XELOX化疗方案联合益髓健脾汤治疗)。比较2组患者的疾病控制率、免疫功能指标CD3+、CD4+、CD8+及CD4+与CD8+的比值(CD4+/CD8+)、肿瘤标志物癌胚抗原(CEA)、糖类抗原125(CA125)及糖类抗原199(CA199)、肠道菌群指标(乳酸杆菌、双歧杆菌、大肠杆菌)及不良反应发生情况。
    结果 治疗后，观察组疾病控制率为85.00%, 高于对照组的65.00%, 差异有统计学意义(P < 0.05); 治疗后, 2组T淋巴细胞亚群CD3+、CD4+水平和CD4+/CD8+以及乳酸杆菌、双歧杆菌数量较治疗前升高，且观察组高于对照组，差异有统计学意义(P < 0.05); 治疗后, 2组患者CD8+水平和CEA、CA125、CA199水平以及大肠杆菌数量均降低，且观察组低于对照组，差异有统计学意义(P < 0.05)。观察组不良反应总发生率为17.50%, 低于对照组的42.50%, 差异有统计学意义(P < 0.05)。
    结论 采用益髓健脾汤联合XELOX化疗方案治疗结直肠癌可提高疗效，调整肠道菌群分布，增强免疫功能，降低不良反应发生率。

     

    Abstract:
    Objective To explore the effects of Yisui Jianpi Decoction combined with XELOX chemotherapy on immune function and gut microbiota in patients with colorectal cancer.
    Methods Eighty patients with colorectal cancer (CRC) were selected as the study subjects, and were randomly divided into control group (40 cases, XELOX chemotherapy) and observation group (40 cases, Yisui Jianpi Decoction based on the control group). The disease control rate, immune function indicatorsCD3+, CD4+, CD8+, and CD4+-to-CD8+ratio(CD4+/CD8+), tumor markers carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and carbohydrate antigen 199 (CA199), gut microbiota indicators (Lactobacillus, Bifidobacterium, Escherichia coli), and occurrence of adverse reactions were compared between the two groups.
    Results After treatment, the disease control rate in the observation group was 85.00% (34/40), which was obviously higher than 65.00% (26/40) in the control group (P < 0.05); after treatment, the number of T lymphocyte subsets CD3+, CD4+, CD4+/CD8+, the number of Lactobacillus and Bifidobacterium in the two groups obviously increased, and the observation group were higher than the control group (P < 0.05); after treatment, the levels of CD8+, CEA, CA125, CA199, and the number of Escherichia coli in both groups decreased, and the observation group was lower than the control group (P < 0.05). The total incidence of adverse reactions in the observation group was 17.50% (7/40), which was lower than 42.50% (17/40) in the control group (P < 0.05).
    Conclusion The combination of Yisui Jianpi Decoction and XELOX chemotherapy can improve the therapeutic effect of colorectal cancer, adjust the distribution of intestinal flora, improve immune function, and reduce incidence of adverse reactions.

     

    • HTML全文
    • 参考文献(23)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回